Harald Reinhart has sold ZLAB and made no open-market buys since Apr 2021

Dr. Harald Reinhart is a biopharmaceutical executive and physician who has served as President, Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Limited, and previously as the company’s Chief Medical Officer, Autoimmune and Infectious Diseases.( Over roughly a decade at Zai Lab, he led global development efforts in infectious diseases and later significantly expanded the company’s capabilities across neuroscience and autoimmune indications.( As a corporate insider, he has engaged in reported transactions of Zai Lab American Depositary Shares (ADS), including acquisitions and sales disclosed in SEC filings and market reports.(

Zai Lab announced in June 2024 that Dr. Reinhart decided to retire from his role as President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases, effective June 30, 2024, with no disagreements related to the company’s operations, policies, or practices, and that he would continue to serve as a senior advisor to the company.( Prior to and during his tenure at Zai Lab, he brought extensive infectious disease expertise and leadership experience in clinical development, supporting the company’s growth as a global, innovation-driven biopharmaceutical enterprise.( Public filings and company communications identify him as Dr. Harald Reinhart, indicating a medical or doctoral education background, although specific degrees and institutions are not detailed in the available records.(

Written by Perplexity from public sources.